Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | POLB | P06746 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18158939 | 0.74 | PSMD14 (0.38) | SMN1; SMN2MAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL14281320 | 0.73 | MEN1 (0.43) | SMN1; SMN2MAPTPOLBL3MBTL1MAPK1 | |
| SCHEMBL14281301 | 0.69 | KMT2A (0.46) | SMN1; SMN2MAPTPOLBL3MBTL1MAPK1 | |
| SCHEMBL13755332 | 0.69 | KMT2A (0.46) | SMN1; SMN2MAPTPOLBL3MBTL1MAPK1 | |
| SCHEMBL17111550 | 0.65 | MAPT (0.50) | SMN1; SMN2PDE7AMAPTPOLBL3MBTL1 | |
| SCHEMBL12709581 | 0.64 | PDE7A (0.43) | SMN1; SMN2PDE7AMAPTPOLBL3MBTL1 | |
| SCHEMBL1625709 | 0.64 | MAPT (0.44) | PDE7AMAPTPOLBL3MBTL1MAPK1 | |
| SCHEMBL18158922 | 0.63 | PSMD14 (0.42) | SMN1; SMN2MAPTPOLBMAPK1MEN1 | |
| SCHEMBL13402976 | 0.63 | POLB (0.43) | SMN1; SMN2MAPTPOLBMAPK1MEN1 | |
| SCHEMBL29859154 | 0.62 | TSHR (0.47) | SMN1; SMN2MAPTALDH1A1HCAR3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304459-A1 | NOVEL COMPOUND, PRODUCTION METHOD THEREFOR, AND APPLICATION THEREFOR | TOKYO UNIVERSITY OF PHARMACY & LIFE SCIENCES (JP) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304459-A1 | NOVEL COMPOUND, PRODUCTION METHOD THEREFOR, AND APPLICATION THEREFOR | VIP, MRPL21, THEM6 | SMN1; SMN2 4755/4885PDE7A 1440/4885MAPT 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.